RayKnowChina Research Map
Shortlist

RecruitingPancreatic cancerPhase 1/Phase 2

Registered title, quoted from ClinicalTrials.gov

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

An open trial on pancreatic cancer, registered on ClinicalTrials.gov. Led by Changhai Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorChanghai Hospital海军军医大学第一附属医院(长海医院)ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT04146298, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Patients with measurable and pathologically confirmed advanced pancreatic cancer, including metastatic pancreatic cancer (who have received standard chemotherapy) and recurrent pancreatic cancer (who have received surgery and adjuvant chemotherapy previously).

    Inclusion criterion 1

  3. Absolute neutrophil count of at least 1000/mm\^3.

    Inclusion criterion 12

    Platelet count of at least 100,000/mm\^3.

    Inclusion criterion 14

    Hemoglobin > 8.0 g/dL.

    Inclusion criterion 15

    Serum ALT/AST less than or equal to 3.0 x ULN.

    Inclusion criterion 17

    Total bilirubin less than or equal to 1.5 mg/dL, unless the patient has Gilbert's Syndrome in which case total bilirubin must be less than or equal to 3.0 mg/dL.

    Inclusion criterion 18

    Serum creatinine less than or equal to 1.6 mg/dL.

    Inclusion criterion 19

  4. Women who are pregnant or breastfeeding.

    Exclusion criterion 1

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04146298, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Patients with measurable and pathologically confirmed advanced pancreatic cancer, including metastatic pancreatic cancer (who have received standard chemotherapy) and recurrent pancreatic cancer (who have received surgery and adjuvant chemotherapy previously).
  • Patient's tumor must express the KRAS G12V mutation, or a G12V mutation in HRAS or NRAS, as determined by DNA or RNA sequencing methods.
  • Patients must be HLA-A*11:01.
  • Patients with brain metastasis may be eligible if they are asymptomatic and there are fewer than 3 brain lesions that are each less than 1 cm in diameter.
  • Patients between 18 to 75 years old are eligible.
  • Patients should have good clinical performance status (ECOG 0 or 1).
  • Patients must practice birth control once enrolled into the study and for up to four months after therapy.
  • Patients must be seronegative for HIV antibody.
  • Patients must be seronegative for hepatitis B surface antigen and core antibody (or HBV non-detectable by QPCR).
  • Patients must be seronegative for hepatitis C antibody (or HCV non-detectable by QPCR).
  • Baseline hematology criteria:
  • Absolute neutrophil count of at least 1000/mm\^3.
  • White blood cell count of at least 3000/mm\^3.
  • Platelet count of at least 100,000/mm\^3.
  • Hemoglobin > 8.0 g/dL.
  • Baseline chemistry criteria:
  • Serum ALT/AST less than or equal to 3.0 x ULN.
  • Total bilirubin less than or equal to 1.5 mg/dL, unless the patient has Gilbert's Syndrome in which case total bilirubin must be less than or equal to 3.0 mg/dL.
  • Serum creatinine less than or equal to 1.6 mg/dL.
  • Anticipated lifespan greater than 12 weeks.
  • Patients must be willing and able to comply with all study-related procedures and follow-up requirements.
  • Patients must be able to understand and sign a written Informed Consent Document as well as a durable power of attorney.

Exclusion Criteria:

  • Women who are pregnant or breastfeeding.
  • Patients with any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease or HIV).
  • Patients with active systemic infections, coagulation disorders, or any other major medical illnesses.
  • Patients with concurrent opportunistic infections.
  • Patients on concurrent systemic steroid therapy.
  • Patients with a history of severe immediate hypersensitivity reaction to any of the medicines used in this study (e.g., cyclophosphamide, fludarabine).
  • Patients with active coronary ischemic symptoms.
  • Patients who are receiving any other investigational agents.

Quoted from ClinicalTrials.gov, NCT04146298, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT04146298, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT04146298